The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future.
Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.
About the PMCPA
The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI.
The PMCPA is a division of the ABPI. The Code covers the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines.
If you have any concerns about the activities of pharmaceutical companies in this regard, please contact the PMCPA at 7th Floor, 105 Victoria St, London, SW1E 6QT or mail: email@example.com.
PMCPA Press Office
T: 07920 863650
The ABPI requests that companies collate all internal comments to provide one overall response per company.
The timescales take account of the need for a period of training and familiarisation with the new layout of the Code.
Further explanation of the changes is on the PMCPA website, and other key elements of the changes are below.
Because of the new layout into six sections, the new version has seen some clauses and supplementary information:
Changes as a consequence of EFPIA updates include:
Other changes include: